Economic Times | Natco seeks to block Gilead's hepatitis C drug patent in India: source Reuters Gilead, whose medicine has been hailed by doctors as a breakthrough in treating the liver-destroying disease, has come under fire over its product's $1,000 per pill price tag in the United States. India's patent laws allow a third party to dispute the ... WHO joins clamour to make new hepatitis C pills affordable Gilead aims to license hepatitis C drug to 3-4 Indian firms US drug industry group defends price of Gilead hepatitis drug |
